April 14, 2026 PDL Review Panel Agenda

NC Department of Health and Human Services logo and North Carolina state seal

NC MEDICAID
DIVISION OF HEALTH BENEFITS

PREFERRED DRUG LIST REVIEW PANEL MEETING AGENDA

Tuesday, April 14, 2026, 1:00 p.m.– 5:00 p.m.
In Person and Virtual Online Meeting

I. Welcome

II. Introductions / Medicaid Updates

III. Overview of Panel Activities and Procedures

IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:

Analgesics

  1. NSAIDS

Anticonvulsants

  1. Second Generation

Anti-Infectives – Systemic

  1. Antibiotics: Penicillins, Cephalosporins and Related
  2. Antibiotics: Macrolides and Ketolides
  3. Antibiotics: Quinolones
  4. Antivirals (Hepatitis B Agents)
  5. Antivirals (Hepatitis C Agents)
  6. Antivirals (Influenza)

Behavioral Health

  1. Antihyperkinesis / ADHD
  2. Injectable Antipsychotics: Injectable Long Acting
  3. Atypical Antipsychotics: Oral / Transdermal

Cardiovascular

  1. Ace Inhibitors
  2. Ace Inhibitor / Calcium Channel Blocker Combinations
  3. Angiotensin II Receptor / Neprilysin Blocker
  4. Anti-arrhythmic
  5. Nitrate Combination
  6. Non-dihydropyridine Calcium Channel Blockers
  7. Platelet Inhibitors
  8. Sympatholytics And Combinations

Central Nervous System

  1. Antimigraine Agents
  2. Anti-parkinson And Restless Leg Syndrome Agents
  3. Multiple Sclerosis (Oral)
  4. Amyotrophic Lateral Sclerosis (ALS) Agents

Endocrinology

  1. Growth Hormone
  2. Intermediate Acting Insulin

Hematologic

  1. Colony Stimulating Factors

Ophthalmic

  1. Antibiotics
  2. Antibiotics-Steroid Combinations
  3. Alpha 2 Adrenergic Agents
  4. Beta Blocker Agents / Combinations
  5. Prostaglandin Agonists

Osteoporosis

  1. Bone Resorption Suppression and Related Agents

Otic

  1. Antibiotics
  2. Anti-inflammatory

Respiratory

  1. Beta-adrenergic, Nebulizers
  2. Beta-adrenergic, Oral
  3. Inhaled Corticosteroid Combinations
  4. Low Sedating Antihistamines
  5. Low Sedating Antihistamine Combinations
  6. First Generation Antihistamines

Topicals

  1. Androgenic Agents
  2. Antiviral
  3. Rosacea Agents
  4. Steroids (High Potency)

Miscellaneous

  1. Immunomodulators, Asthma
  2. Weight Management Agents: GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimemetics)
  3. Estrogen Agents, Combinations
  4. Estrogen Agents, Oral / Transdermal
  5. Glucocorticoid Steroids, Oral
  6. Cytokine And Cam Antagonists
  7. Movement Disorders
  8. Skeletal Muscle Relaxants
  9. Continuous Glucose Monitor Sensors

Obsolete Drugs

  1. Obsolete drugs and no long rebate eligible

V. Closing comments and adjournment

On